Eden Biologics adds Henlius’ Scott Liu to its board of directors, as  both King & Spalding and Gedeon Richter also make fresh appointments. And Stada has extended the tenure of CEO Peter Goldschmidt.

Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

As sponsors and US FDA continue to face fallout, newly launched digital archive of industry documents from opioid litigation and settlements will be free public resource for those investigating activities that led to the opioid epidemic. It is modeled on the archive of tobacco industry documents, which has been the basis of about 1,000 scientific publications.